VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 588 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2015. The put-call ratio across all filers is 2.30 and the average weighting 1.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $5,310,000 | -23.5% | 481,390 | +0.7% | 0.82% | -23.3% |
Q4 2016 | $6,942,000 | -18.6% | 478,125 | +37.6% | 1.07% | -14.7% |
Q3 2016 | $8,528,000 | +37.4% | 347,368 | +12.7% | 1.26% | +38.2% |
Q2 2016 | $6,206,000 | -31.2% | 308,142 | -10.1% | 0.91% | -19.9% |
Q1 2016 | $9,019,000 | -73.6% | 342,916 | +2.0% | 1.13% | -73.4% |
Q4 2015 | $34,186,000 | -35.5% | 336,306 | +13.3% | 4.26% | -32.4% |
Q3 2015 | $52,967,000 | -21.2% | 296,931 | -1.9% | 6.30% | -11.9% |
Q2 2015 | $67,248,000 | +14.6% | 302,715 | +2.5% | 7.16% | +5.9% |
Q1 2015 | $58,656,000 | +40.0% | 295,320 | +0.9% | 6.76% | +46.7% |
Q4 2014 | $41,903,000 | +7.6% | 292,802 | -1.4% | 4.61% | -0.1% |
Q3 2014 | $38,949,000 | +2.8% | 296,871 | -1.2% | 4.61% | +6.3% |
Q2 2014 | $37,892,000 | -5.3% | 300,446 | -1.0% | 4.34% | -14.2% |
Q1 2014 | $40,015,000 | -7.9% | 303,536 | -17.9% | 5.05% | -6.2% |
Q4 2013 | $43,426,000 | -26.8% | 369,896 | -34.9% | 5.39% | -1.0% |
Q3 2013 | $59,294,000 | – | 568,332 | – | 5.44% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |